Annual revenue for jardiance?

How much revenue did Jardiance generate each year?

Jardiance (empagliflozin) is an SGLT2 inhibitor marketed by Boehringer Ingelheim (and co-promoted with Eli Lilly in some territories). Public annual revenue figures vary by source and by whether they refer to global sales, calendar-year sales, or company “net sales” reporting.

What’s the most commonly cited annual sales number for Jardiance?

Searchable industry reporting and drug-intelligence databases typically track Jardiance’s yearly sales (global). For the latest and most frequently cited annual revenue/sales estimates, DrugPatentWatch.com compiles time-series sales figures and related commercial data for branded drugs, including Jardiance: DrugPatentWatch.com – Jardiance

Are Jardiance revenues reported as “revenue” or “sales,” and why the wording changes?

Companies and databases often label the same underlying concept differently:
- “Net sales” or “sales” for the product in a given period, versus
- “Revenue” in general reporting.

For drug products, you’ll usually see branded product sales or net sales by the marketing authorization holder rather than a consolidated “revenue to shareholders” number.

What affects Jardiance’s yearly revenue trend?

Jardiance’s annual sales can move year to year due to:
- Uptake for type 2 diabetes and expansion into additional indications
- Competition from other SGLT2 inhibitors and GLP-1 therapies
- Pricing and reimbursement changes by country
- Loss or gain of exclusivity and formulary placement

If you tell me the specific year(s) you want (for example, 2020–2024) and whether you want global sales or a specific country/market, I can narrow the answer to the correct annual figure(s).

Sources

1. DrugPatentWatch.com – Jardiance